Hỏi đáp

Hỏi : I'd like a phonecard, please http://www.lepac.preac.unicamp.br/wp-content/uploads/pharmacy/index.php/stmap_18mwvid.html harga untuk mentato The drug in question is vercirnon, an inhibitor of the chemokine receptor known as CCR9. Last month, GSK published data from the first of four Phase III studies in patients with moderately-to-severely active Crohn’s disease which showed that the drug did not achieve the primary endpoint of improvement in response and the key secondary endpoint of remission.

Đáp :